|
US5969145A
(en)
*
|
1996-08-30 |
1999-10-19 |
Novartis Ag |
Process for the production of epothilones and intermediate products within the process
|
|
ES2312695T3
(es)
*
|
1996-11-18 |
2009-03-01 |
Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) |
Epotilones e y f.
|
|
US20050043376A1
(en)
*
|
1996-12-03 |
2005-02-24 |
Danishefsky Samuel J. |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
|
US6867305B2
(en)
|
1996-12-03 |
2005-03-15 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
CA2273083C
(en)
|
1996-12-03 |
2012-09-18 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
|
US6204388B1
(en)
|
1996-12-03 |
2001-03-20 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
US6380394B1
(en)
|
1996-12-13 |
2002-04-30 |
The Scripps Research Institute |
Epothilone analogs
|
|
US6441186B1
(en)
|
1996-12-13 |
2002-08-27 |
The Scripps Research Institute |
Epothilone analogs
|
|
US6660758B1
(en)
*
|
1996-12-13 |
2003-12-09 |
The Scripps Research Institute |
Epothilone analogs
|
|
US6605599B1
(en)
|
1997-07-08 |
2003-08-12 |
Bristol-Myers Squibb Company |
Epothilone derivatives
|
|
ES2290993T3
(es)
|
1997-08-09 |
2008-02-16 |
Bayer Schering Pharma Aktiengesellschaft |
Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
|
|
US6365749B1
(en)
*
|
1997-12-04 |
2002-04-02 |
Bristol-Myers Squibb Company |
Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
|
|
US6683100B2
(en)
|
1999-01-19 |
2004-01-27 |
Novartis Ag |
Organic compounds
|
|
US6194181B1
(en)
|
1998-02-19 |
2001-02-27 |
Novartis Ag |
Fermentative preparation process for and crystal forms of cytostatics
|
|
US6302838B1
(en)
|
1998-02-25 |
2001-10-16 |
Novartis Ag |
Cancer treatment with epothilones
|
|
FR2775187B1
(fr)
|
1998-02-25 |
2003-02-21 |
Novartis Ag |
Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
|
|
US6498257B1
(en)
*
|
1998-04-21 |
2002-12-24 |
Bristol-Myers Squibb Company |
2,3-olefinic epothilone derivatives
|
|
US6399638B1
(en)
*
|
1998-04-21 |
2002-06-04 |
Bristol-Myers Squibb Company |
12,13-modified epothilone derivatives
|
|
DE19826988A1
(de)
|
1998-06-18 |
1999-12-23 |
Biotechnolog Forschung Gmbh |
Epothilon-Nebenkomponenten
|
|
WO2000031247A2
(en)
|
1998-11-20 |
2000-06-02 |
Kosan Biosciences, Inc. |
Recombinant methods and materials for producing epothilone and epothilone derivatives
|
|
US6410301B1
(en)
|
1998-11-20 |
2002-06-25 |
Kosan Biosciences, Inc. |
Myxococcus host cells for the production of epothilones
|
|
PT1140944E
(pt)
|
1998-12-22 |
2004-01-30 |
Novartis Pharma Gmbh |
Derivados de epotilona e sua utilizacao como agentes antitumorais
|
|
US6780620B1
(en)
*
|
1998-12-23 |
2004-08-24 |
Bristol-Myers Squibb Company |
Microbial transformation method for the preparation of an epothilone
|
|
HK1044946A1
(zh)
*
|
1999-02-11 |
2002-11-08 |
舍林股份公司 |
依泊昔酮衍生物、其製備方法及藥物用途
|
|
EP1169038B9
(en)
|
1999-04-15 |
2013-07-10 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
US7125893B1
(en)
|
1999-04-30 |
2006-10-24 |
Schering Ag |
6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
|
|
AU775373B2
(en)
|
1999-10-01 |
2004-07-29 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
US6518421B1
(en)
|
2000-03-20 |
2003-02-11 |
Bristol-Myers Squibb Company |
Process for the preparation of epothilone analogs
|
|
DE10020899A1
(de)
*
|
2000-04-20 |
2001-10-25 |
Schering Ag |
9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
|
|
US6489314B1
(en)
|
2001-04-03 |
2002-12-03 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
|
WO2001092255A2
(en)
*
|
2000-05-26 |
2001-12-06 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
|
UA75365C2
(en)
*
|
2000-08-16 |
2006-04-17 |
Bristol Myers Squibb Co |
Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
|
|
IL155306A0
(en)
|
2000-10-13 |
2003-11-23 |
Univ Mississippi |
Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby
|
|
ES2304240T3
(es)
|
2001-01-25 |
2008-10-01 |
Bristol-Myers Squibb Company |
Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer.
|
|
EE200300323A
(et)
*
|
2001-01-25 |
2003-10-15 |
Bristol-Myers Squibb Company |
Epotilooni analoogi sisaldav parenteraalne ravimpreparaat, meetod selle valmistamiseks ning kasutamine
|
|
WO2002058699A1
(en)
*
|
2001-01-25 |
2002-08-01 |
Bristol-Myers Squibb Company |
Pharmaceutical forms of epothilones for oral administration
|
|
MXPA03006412A
(es)
*
|
2001-01-25 |
2003-10-15 |
Bristol Myers Squibb Co |
Metodos para administrar analogos de epotilona para tratamiento de cancer.
|
|
US6893859B2
(en)
|
2001-02-13 |
2005-05-17 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
|
KR20040028720A
(ko)
|
2001-02-20 |
2004-04-03 |
브리스톨-마이어스스퀴브컴파니 |
치료불응성 종양 치료용 에포틸론 유도체
|
|
CN1774253A
(zh)
*
|
2001-02-20 |
2006-05-17 |
布里斯托尔-迈尔斯斯奎布公司 |
用环氧丙酯酮衍生物治疗顽固性肿瘤
|
|
NZ527557A
(en)
|
2001-02-27 |
2005-05-27 |
Biotechnolog Forschung Gmbh |
Degradation of epothilones and ethynyl substituted epothilones
|
|
IL157443A0
(en)
*
|
2001-03-14 |
2004-03-28 |
Bristol Myers Squibb Co |
Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
|
|
MXPA03010909A
(es)
|
2001-06-01 |
2004-02-17 |
Bristol Myers Squibb Co |
Derivados de epotilona.
|
|
TWI315982B
(en)
*
|
2001-07-19 |
2009-10-21 |
Novartis Ag |
Combinations comprising epothilones and pharmaceutical uses thereof
|
|
MXPA04006822A
(es)
|
2002-01-14 |
2004-12-08 |
Novartis Ag |
Combinaciones que comprenden epotilonas y anti-metabolitos.
|
|
EP1340498A1
(en)
*
|
2002-03-01 |
2003-09-03 |
Schering Aktiengesellschaft |
Use of epothilones in the treatment of brain diseases associated with proliferative processes
|
|
AU2003218107A1
(en)
*
|
2002-03-12 |
2003-09-29 |
Bristol-Myers Squibb Company |
C12-cyano epothilone derivatives
|
|
SI1483251T1
(sl)
|
2002-03-12 |
2010-03-31 |
Bristol Myers Squibb Co |
C cian epotilonski derivati
|
|
TW200403994A
(en)
|
2002-04-04 |
2004-03-16 |
Bristol Myers Squibb Co |
Oral administration of EPOTHILONES
|
|
TW200400191A
(en)
*
|
2002-05-15 |
2004-01-01 |
Bristol Myers Squibb Co |
Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
|
|
US7405234B2
(en)
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
|
WO2003105828A1
(en)
|
2002-06-14 |
2003-12-24 |
Bristol-Myers Squibb Company |
Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
|
|
DE10232094A1
(de)
*
|
2002-07-15 |
2004-02-05 |
GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) |
5-Thiaepothilone und 15-disubstituierte Epothilone
|
|
US7649006B2
(en)
|
2002-08-23 |
2010-01-19 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
US6921769B2
(en)
|
2002-08-23 |
2005-07-26 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
|
EP2186811A1
(en)
|
2002-08-23 |
2010-05-19 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
|
AU2003275068B2
(en)
|
2002-09-23 |
2009-09-17 |
Bristol-Myers Squibb Company |
Methods for the preparation, isolation and purification of epothilone B, and X-Ray crystal structures of epothilone B
|
|
CA2501610C
(en)
*
|
2002-10-11 |
2012-01-03 |
Dana-Farber Cancer Institute Inc |
Epothilone derivatives for the treatment of multiple myeloma
|
|
WO2004045518A2
(en)
|
2002-11-15 |
2004-06-03 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
|
US7645782B2
(en)
*
|
2002-11-28 |
2010-01-12 |
Wolfgang Richter |
Thia-epothilone derivatives for the treatment of cancer
|
|
BR0317150A
(pt)
*
|
2002-12-09 |
2005-11-01 |
Novartis Ag |
Estabilizadores de microtúbulos em stents para o tratamento de estenose
|
|
GB0230024D0
(en)
*
|
2002-12-23 |
2003-01-29 |
Novartis Ag |
Organic compounds
|
|
CN100359014C
(zh)
*
|
2003-01-28 |
2008-01-02 |
北京华昊中天生物技术有限公司 |
一类新型埃坡霉素化合物及其制备方法和用途
|
|
WO2004071440A2
(en)
|
2003-02-06 |
2004-08-26 |
Bristol-Myers Squibb Company |
Thiazolyl-based compounds useful as kinase inhibitors
|
|
GB0305928D0
(en)
*
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
|
AU2008200555C1
(en)
*
|
2003-03-14 |
2011-12-15 |
Novartis Ag |
Treatment of proliferative diseases with epothilone derivatives and radiation
|
|
US7371759B2
(en)
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
|
DE10344882A1
(de)
|
2003-09-26 |
2005-04-21 |
Morphochem Ag Komb Chemie |
Neue Makrocyclen zur Behandlung von Krebserkrankungen
|
|
US20050171167A1
(en)
*
|
2003-11-04 |
2005-08-04 |
Haby Thomas A. |
Process and formulation containing epothilones and analogs thereof
|
|
WO2005054429A2
(en)
*
|
2003-11-19 |
2005-06-16 |
The University Of Mississippi |
Synthesis of the c1-c6 keto-acid synthon of the epothilones
|
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
|
EP1559447A1
(en)
|
2004-01-30 |
2005-08-03 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
|
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
|
US7696241B2
(en)
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
|
US7459562B2
(en)
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
|
TW200538453A
(en)
|
2004-04-26 |
2005-12-01 |
Bristol Myers Squibb Co |
Bicyclic heterocycles as kinase inhibitors
|
|
US20090004277A1
(en)
*
|
2004-05-18 |
2009-01-01 |
Franchini Miriam K |
Nanoparticle dispersion containing lactam compound
|
|
US7432373B2
(en)
|
2004-06-28 |
2008-10-07 |
Bristol-Meyers Squibb Company |
Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
|
|
US7439246B2
(en)
|
2004-06-28 |
2008-10-21 |
Bristol-Myers Squibb Company |
Fused heterocyclic kinase inhibitors
|
|
US7173031B2
(en)
|
2004-06-28 |
2007-02-06 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
|
WO2006017761A2
(en)
*
|
2004-08-05 |
2006-02-16 |
Emory University |
Epothilone analogues as therapeutic agents
|
|
EP1640004A1
(en)
*
|
2004-09-24 |
2006-03-29 |
Schering Aktiengesellschaft |
Use of epothilones in the treatment of bone metastases and bone tumors or cancers
|
|
AR052142A1
(es)
|
2004-11-18 |
2007-03-07 |
Bristol Myers Squibb Co |
Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma
|
|
EP1824458A1
(en)
*
|
2004-11-18 |
2007-08-29 |
Bristol-Myers Squibb Company |
Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
|
|
US20060121511A1
(en)
|
2004-11-30 |
2006-06-08 |
Hyerim Lee |
Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
|
|
EP1674098A1
(en)
|
2004-12-23 |
2006-06-28 |
Schering Aktiengesellschaft |
Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
|
|
US7754850B2
(en)
|
2005-02-11 |
2010-07-13 |
University Of Southern California |
Chimeric disintegrin domain
|
|
JP4954983B2
(ja)
|
2005-05-18 |
2012-06-20 |
ファーマサイエンス・インコーポレイテッド |
Ｂｉｒドメイン結合化合物
|
|
US7348325B2
(en)
|
2005-11-30 |
2008-03-25 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
|
JP2009532035A
(ja)
|
2006-03-31 |
2009-09-10 |
ブリストル−マイヤーズ スクイブ カンパニー |
微小管安定化剤に対する感受性を決定するためのバイオマーカーおよび方法
|
|
EP2029156A4
(en)
*
|
2006-05-01 |
2010-07-21 |
Univ Southern California |
COMBINATION THERAPY FOR CANCER TREATMENT
|
|
CN101535300B
(zh)
|
2006-05-16 |
2014-05-28 |
埃格拉医疗公司 |
Iap bir域结合化合物
|
|
JP2010511408A
(ja)
|
2006-12-04 |
2010-04-15 |
ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ |
癌をＣｐＧリッチＤＮＡおよびキュプレドキシンで治療するための組成物および方法
|
|
JP2010518123A
(ja)
|
2007-02-08 |
2010-05-27 |
ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ |
癌をキュプレドキシンで予防するための組成物および方法
|
|
EP2152717A1
(en)
|
2007-05-25 |
2010-02-17 |
Bristol-Myers Squibb Company |
Processes for making epothilone compounds and analogs
|
|
US20090076099A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched ixabepilone
|
|
EP2065054A1
(en)
|
2007-11-29 |
2009-06-03 |
Bayer Schering Pharma Aktiengesellschaft |
Combinations comprising a prostaglandin and uses thereof
|
|
EP2070521A1
(en)
|
2007-12-10 |
2009-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Surface-modified nanoparticles
|
|
DE102007059752A1
(de)
|
2007-12-10 |
2009-06-18 |
Bayer Schering Pharma Aktiengesellschaft |
Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
|
|
JP2011509299A
(ja)
*
|
2008-01-08 |
2011-03-24 |
ブリストル−マイヤーズ スクイブ カンパニー |
増殖性疾患治療のための、抗ｃｔｌａ−４抗体とチューブリン調節剤との組み合わせ
|
|
MX2010011209A
(es)
*
|
2008-04-24 |
2010-11-12 |
Squibb Bristol Myers Co |
Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer.
|
|
US8802394B2
(en)
|
2008-11-13 |
2014-08-12 |
Radu O. Minea |
Method of expressing proteins with disulfide bridges with enhanced yields and activity
|
|
EP2210584A1
(en)
|
2009-01-27 |
2010-07-28 |
Bayer Schering Pharma Aktiengesellschaft |
Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
|
|
JP4500951B1
(ja)
*
|
2009-08-07 |
2010-07-14 |
学校法人神戸学院 |
Ｄｎａ合成酵素阻害剤
|
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
|
NZ599830A
(en)
|
2009-11-05 |
2014-08-29 |
Rhizen Pharmaceuticals Sa |
Novel kinase modulators
|
|
US9284350B2
(en)
|
2010-02-12 |
2016-03-15 |
Pharmascience Inc. |
IAP BIR domain binding compounds
|
|
NZ604306A
(en)
|
2010-05-17 |
2015-02-27 |
Incozen Therapeutics Pvt Ltd |
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
|
|
US20110300150A1
(en)
|
2010-05-18 |
2011-12-08 |
Scott Eliasof |
Compositions and methods for treatment of autoimmune and other disease
|
|
KR20130086534A
(ko)
|
2010-06-01 |
2013-08-02 |
플러스 케미칼스, 에스.에이. |
익사베필론의 고체 형태
|
|
CN101906099A
(zh)
*
|
2010-07-16 |
2010-12-08 |
泰州市今朝伟业精细化工有限公司 |
一种埃博霉素d-内酰胺衍生物化学合成方法
|
|
JP5889337B2
(ja)
|
2011-01-20 |
2016-03-22 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
Ｍｒｉマーカー、送達および抜取りシステムならびにこれらの製造方法および使用方法
|
|
WO2012135278A2
(en)
*
|
2011-04-01 |
2012-10-04 |
The Research Foundation Of State University Of New York |
Olefin-triggered acid amplifiers
|
|
WO2012135286A2
(en)
*
|
2011-04-01 |
2012-10-04 |
The Research Foundation Of State University Of New York |
Stabilized acid amplifiers
|
|
PH12013502240B1
(en)
|
2011-05-04 |
2018-06-27 |
Rhizen Pharmaceuticals Sa |
Novel compounds as modulators of protein kinase
|
|
JP2014516075A
(ja)
|
2011-06-06 |
2014-07-07 |
シェブロン フィリップス ケミカル カンパニー エルピー |
癌治療のためのメタロセン化合物の使用
|
|
WO2012171020A1
(en)
|
2011-06-10 |
2012-12-13 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
CN102863474A
(zh)
|
2011-07-09 |
2013-01-09 |
陈小平 |
一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
|
|
WO2013008091A1
(en)
*
|
2011-07-13 |
2013-01-17 |
Xellia Pharmaceuticals Aps |
Manufacturing of epothilone derivatives and the use thereof
|
|
EP2567825B1
(en)
|
2011-09-12 |
2014-04-02 |
Agfa-Gevaert |
Colour laser marking methods of security document precursors
|
|
CN102993239A
(zh)
|
2011-09-19 |
2013-03-27 |
陈小平 |
离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
|
|
EP2793947B1
(en)
|
2011-12-23 |
2021-02-03 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
CN107082779A
(zh)
|
2012-03-30 |
2017-08-22 |
理森制药股份公司 |
作为c‑met 蛋白激酶调节剂的新化合物
|
|
US10132799B2
(en)
|
2012-07-13 |
2018-11-20 |
Innate Pharma |
Screening of conjugated antibodies
|
|
EP3564259A3
(en)
|
2012-11-09 |
2020-02-12 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
|
WO2014075391A1
(zh)
|
2012-11-17 |
2014-05-22 |
北京市丰硕维康技术开发有限责任公司 |
离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
CA2892863C
(en)
|
2012-12-10 |
2022-03-15 |
Mersana Therapeutics, Inc. |
Polymeric scaffold based on phf for targeted drug delivery
|
|
WO2014093640A1
(en)
|
2012-12-12 |
2014-06-19 |
Mersana Therapeutics,Inc. |
Hydroxy-polmer-drug-protein conjugates
|
|
TWI520956B
(zh)
|
2013-03-08 |
2016-02-11 |
台灣神隆股份有限公司 |
伊莎匹隆及其中間體之製備方法
|
|
US10611824B2
(en)
|
2013-03-15 |
2020-04-07 |
Innate Pharma |
Solid phase TGase-mediated conjugation of antibodies
|
|
EP2972394A4
(en)
|
2013-03-15 |
2016-11-02 |
Sloan Kettering Inst Cancer |
HSP90-DESIGNING AND THERAPY
|
|
TN2015000543A1
(en)
|
2013-06-11 |
2017-04-06 |
Bayer Pharma AG |
Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
|
|
EP3010547B1
(en)
|
2013-06-20 |
2021-04-21 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
CN105517577A
(zh)
|
2013-06-21 |
2016-04-20 |
先天制药公司 |
多肽的酶促偶联
|
|
ES2754397T3
(es)
|
2013-10-11 |
2020-04-17 |
Asana Biosciences Llc |
Conjugados de proteína-polímero-fármaco
|
|
KR102087850B1
(ko)
|
2013-10-11 |
2020-03-12 |
메르사나 테라퓨틱스, 인코포레이티드 |
단백질-고분자-약물 접합체
|
|
US10341459B2
(en)
|
2015-09-18 |
2019-07-02 |
International Business Machines Corporation |
Personalized content and services based on profile information
|
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
|
WO2018004338A1
(en)
|
2016-06-27 |
2018-01-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
|
AU2018290330A1
(en)
|
2017-06-22 |
2020-01-02 |
Mersana Therapeutics, Inc. |
Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
WO2019092148A1
(en)
|
2017-11-10 |
2019-05-16 |
Innate Pharma |
Antibodies with functionalized glutamine residues
|
|
AU2019262520B2
(en)
|
2018-05-04 |
2025-07-10 |
Tagworks Pharmaceuticals B.V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
|
CA3099421C
(en)
|
2018-05-04 |
2025-05-06 |
Tagworks Pharmaceuticals B.V. |
COMPOUNDS INCLUDING A BINDER TO INCREASE TRANSCYCLOOCTENE STABILITY
|
|
CN113365664A
(zh)
|
2018-10-29 |
2021-09-07 |
梅尔莎纳医疗公司 |
具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
|
|
US11535634B2
(en)
|
2019-06-05 |
2022-12-27 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
|
DK3983363T3
(da)
|
2019-06-17 |
2024-06-24 |
Tagworks Pharmaceuticals B V |
Forbindelser til hurtig og effektiv klikfrigivelse
|
|
WO2021142202A1
(en)
|
2020-01-10 |
2021-07-15 |
R-Pharm Us Operating Llc |
Compositions of ixabepilone
|
|
WO2022182415A1
(en)
|
2021-02-24 |
2022-09-01 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
|
US20250327057A1
(en)
|
2021-09-06 |
2025-10-23 |
Veraxa Biotech Gmbh |
Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
|
|
WO2023094525A1
(en)
|
2021-11-25 |
2023-06-01 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
|
DK4186529T3
(da)
|
2021-11-25 |
2025-08-25 |
Veraxa Biotech Gmbh |
Forbedrede antistof-payload-konjugater (apc) fremstillet ved stedspecifik konjugering ved hjælp af genetisk kodeudvidelse
|
|
US20250135011A1
(en)
|
2021-12-08 |
2025-05-01 |
European Molecular Biology Laboratory |
Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
|
|
US20250114489A1
(en)
|
2022-02-15 |
2025-04-10 |
Tagworks Pharmaceuticals B.V. |
Masked il12 protein
|
|
CA3261603A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
ANTIBODY-DRUG CONJUGATES
|
|
WO2024080872A1
(en)
|
2022-10-12 |
2024-04-18 |
Tagworks Pharmaceuticals B.V. |
Strained bicyclononenes
|
|
WO2024153789A1
(en)
|
2023-01-20 |
2024-07-25 |
Basf Se |
Stabilized biopolymer composition, their manufacture and use
|
|
WO2024191293A1
(en)
|
2023-03-10 |
2024-09-19 |
Tagworks Pharmaceuticals B.V. |
Trans-cyclooctene with improved t-linker
|
|
KR20260046464A
(ko)
|
2023-07-27 |
2026-04-07 |
베락사 바이오테크 게엠베하 |
친수성 트랜스-시클로옥텐(hyTCO) 화합물, 이를 포함하는 구조체 및 접합체
|
|
WO2025056807A1
(en)
|
2023-09-15 |
2025-03-20 |
Basf Se |
Stabilized biopolymer composition, their manufacture and use
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
WO2025174248A1
(en)
|
2024-02-16 |
2025-08-21 |
Tagworks Pharmaceuticals B.V. |
Trans-cyclooctenes with "or gate" release
|
|
WO2026043376A1
(en)
|
2024-08-22 |
2026-02-26 |
Tagworks Pharmaceuticals B.V. |
Trans-cyclooctene formulations
|
|
WO2026064527A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
|
|
WO2026064520A1
(en)
|
2024-09-19 |
2026-03-26 |
Tesseract Medicines Us, Llc |
Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload
|
|
WO2026078060A1
(en)
|
2024-10-08 |
2026-04-16 |
Basf Se |
Tocopherol alkoxylates for biopolymer stabilization
|